This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Glomerulonephritis
  • /
  • Atrasentan in Patients With IgA Nephropathy (ALIGN...
Clinical trial

Atrasentan in Patients With IgA Nephropathy (ALIGN)

Read time: 1 mins
Last updated:24th Oct 2021
Status: Recruiting
Identifier: NCT04573478
Atrasentan in Patients With IgA Nephropathy (ALIGN)

Brief Summary:

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

Detailed Description:
Approximately 320 patients with biopsy-proven IgAN will be randomized to receive 0.75 mg atrasentan or placebo daily for 132 weeks. Subjects receive a maximally tolerated and stable dose of a RAS (renin-angiotensin system) inhibitor (such as angiotensin converting enzyme inhibitor (ACEi) or angiotensin-receptor antagonist (ARB)) as part of standard of care. An exception will be made for subjects who are unable to tolerate RAS inhibitor therapy.

The primary objective of the study is to evaluate the effect of atrasentan versus placebo on proteinuria as measured by UPCR. Secondary and tertiary objectives include evaluating the change in kidney function over time as measured by eGFR, safety and tolerability, as well as quality of life.

Subjects will have assessments of safety and efficacy over 2 ½ years. To facilitate study participation over this time period, where allowed by local regulations, options for remote study visits using telemedicine and home health may be offered.

Subjects who complete the study may be eligible to enroll in an extension study to receive open-label treatment with atrasentan under a separate protocol.

Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Double-blind
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Actual Study Start Date: December 11, 2020
Estimated Primary Completion Date: December 1, 2023
Estimated Study Completion Date: December 1, 2025

- Experimental: Atrasentan
- Placebo Comparator: Placebo

Category Value
Study type(s) Interventional
Estimated enrolment 320
Actual Study start date 11 December 2020
Estimated Study Completion Date 01 December 2025

View full details